

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2013

Sales of Major Products

Supplemental Data

For information purpose only

(Note) All amounts are rounded off to the nearest hundred million yen.

		2013			Year ending
		Results	Increase/Decrease		March 31,2014 Forecast
Glactiv	Agent for type II diabetes	¥ 348	¥ +69	24.7 %	¥ 400
Opalmon	Circulatory system agent	339	△ 56	△ 14.1 %	310
Onon	Agent for bronchial asthma and allergic rhinitis	161	△ 30	△ 15.6 %	125
Foipan	Agent for chronic pancreatitis and postoperative reflux esophagitis	88	△ 14	△ 13.7 %	80
Kinedak	Agent for diabetic peripheral neuropathy	87	△ 25	△ 22.6 %	80
Emend/Proemend	Agent for Chemotherapy-induced nausea and vomiting	79	+12	18.0 %	95
Recalbon	Agent for osteoporosis	77	+41	117.6 %	105
Onon dry syrup	Agent for pediatric bronchial asthma and allergic rhinitis	73	△ 3	△ 3.7 %	70
Staybla	Agent for overactive bladder (pollakiuria and urinary incontinence)	64	+3	5.3 %	70
Rivastach	Agent for Alzheimer's disease	39	+27	216.9 %	65
Elaspol	Agent for acute lung injury associated with SIRS	39	△ 5	△ 10.9 %	35
Onoact	Agent for tachyarrhythmia during and post operation	37	+4	10.5 %	45

Note: Sales of products are shown in a gross sales basis.